# Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects

> **NCT07345442** · PHASE1 · COMPLETED · sponsor: **Anhui Palo Alto Pharmaceuticals, Inc.** · enrollment: 36 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **DRUG:** PA9159 nasal spray solution, 80 μg one day treatment
- **DRUG:** PA9159 nasal spray solution, 160 μg one day treatment
- **DRUG:** PA9159 nasal spray solution, 320 μg one day treatment
- **DRUG:** PA9159 nasal spray solution, 80 μg 7-day treatment
- **DRUG:** PA9159 nasal spray solution, 160 μg 7-day treatment
- **DRUG:** PA9159 nasal spray solution, 320 μg 7-day treatment
- **DRUG:** Placebo, the same intranasal spray solution without PA9159 active ingredient

## Key facts

- **NCT ID:** NCT07345442
- **Lead sponsor:** Anhui Palo Alto Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-14
- **Primary completion:** 2025-06-09
- **Final completion:** 2025-06-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07345442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07345442, "Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07345442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*